P-371: Bortezomib thalidomide dexamethasone as first-line treatment in Newly Multiple Myeloma Patients in Perú.

Introduction: Treatment in multiple myeloma is based on triplet or quadruplet including lenalidomide, however in low-and middle-income countries novel therapies are not readily available. Bortezomib thalidomide dexamethasone (VTd) is the standard treatment in our institution. We aimed to determine the outcomes with VTd regimen.

Methods: We review retrospectively medical records of patients with newly diagnosed multiple myeloma treated at the National Cancer Institute in Perú from 2015-2018. Baseline characteristics were evaluated. Overall survival was analyzed using STATA program.

Results: During the period of study 16 patients were included. The median age was 54 (range 31-69). Most were male (69%). Ig G Myeloma was seen in 56%, followed by Ig A (25%). 62% were ISS II. Complete response was obtained in 50%, followed by 25% of very good partial response. Cytogenetics risk stratification was not available. The median follow-up was 66.5 months. The median overall survival was not achieved. The 5-y OS was 68.75% (95 IC, 40.4-85.6)

Conclusions: Bortezomib thalidomide dexamethasone is highly effective in patients with newly diagnosed multiple myeloma which is similar to international literature. Overall survival is good compared to other reports; however, the lack of the availability FISH test is very important to stratify our patient in order to give a better treatment.